Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05805605 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Allo HSCT Using RIC and PTCy for Hematological Diseases

StatusRecruiting
PhasePhase 2
Started2023-05-01
View on ClinicalTrials.gov ↗

Amendment history

2026-07-02
4 amendments v3-v6
4 re-verifications since 2024-05-06, no change to tracked fields
2023-05-02
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-07-01→confirmed 2023-05-01
Study sitesdetails revised at 1 of 1 site
2023-04-18
Study Status v1
Start date2023-04-01→2023-07-01
2023-03-27
Original filing
This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.
Trial Details
NCT Number NCT05805605
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes +10 more
Enrollment 56 participants
Start Date 2023-05-01
Primary Completion 2027-10-22 (estimated)
Study Completion 2028-10-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-06